The purpose of this study was to characterize children with Down syndrome and attention-deficit hyperactivity disorder (ADHD) with disruptive behaviors using the Aberrant Behavior Checklist (ABC), and to measure the treatment effects of guanfacine on maladaptive behaviors. Subjects were enrolled from a group of outpatients who visited our clinic between 2002 and 2007. Subjects (N = 23) were children with Down syndrome ages 4 to 12 years (mean 7.4 ± 4.1), who met criteria for ADHD according to the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition. The Aberrant Behavior Checklist Irritability and Hyperactivity subscales each showed a significant decrease (P < .0001) at follow-up. The mean decline on Hyperactivity was 25% (–7.8 points), and for Irritability, 25% (–3.5 points). The mean composite score also declined by 24% (–12 points). Effect size differences on Irritability were moderate, whereas differences on Hyperactivity and composite score appeared large. Clinically important target behaviors were reduced. Medication was generally well tolerated and the incidence of treatment emergent side effects remained low.
GreenJMDennisJBennetsLA. Attention disorder in a group of young Down’s syndrome children. J Ment Defic Res. 1989;33:105–122.
2.
PueschelSMBernierJCPezzulloJC. Behavioural observations in children with Down’s syndrome. J Ment Defic Res. 1991;35:502–511.
3.
LalondeJTurgayAHudsonJI. Attention-deficit hyperactivity disorder subtypes and comorbid disruptive behavior disorders in child and adolescent mental health clinic. Can J Psychiatry. 1998;43:623–628.
4.
FeeleyKJonesE. Addressing challenging behaviour in children with Down syndrome: the use of applied behavior analysis for assessment and intervention. Downs Syndr Res Pract. 2006;11:64–77.
5.
CaponeGGoyalPAresW. Neurobehavioral disorders in children, adolescents, and young adults with Down syndrome. Am J Med Genet C Semin Med Genet. 2006;142C:158–172.
6.
ZametkinAJRapoportJL. Neurobiology of attention deficit disorder with hyperactivity: where have we come in 50 years?J Am Acad Child Adolesc Psychiatry. 1987;26:676–686.
7.
ShawPEckstrandKSharpW. Attention-deficit/hyperactivity disorder is characterized by a delay in cortical maturation. Proc Natl Acad Sci U S A. 2007;104:19649–19654.
8.
ArnstenAFPliszkaSR. Catecholamine influences on prefrontal cortical function: relevance to treatment of attention deficit/hyperactivity disorder and related disorders. Pharmacol Biochem Behav. 2011;99:211–216.
9.
PrinceJ. Catecholamine dysfunction in attention-deficit/hyperactivity disorder. J Clin Psychopharm. 2008;28:S39–S45.
10.
CorteseSCastelnauPMorcilloC. Psychostimulants for ADHD-like symptoms in individuals with autism spectrum disorders. Expert Rev Neurother. 2012;12:461–473.
11.
AmanMGBuicanBArnoldLE. Methylphenidate treatment in children with borderline IQ and mental retardation: analysis of three aggregated studies. J Child Adolesc Psychopharm. 2003;13:29–40.
12.
OwensJAMoturiS. Pharmacologic treatment of pediatric insomnia. Child Adolesc Psychiatr Clin N Am. 2009;18:1001–1016.
13.
RamosBPArnstenAF. Adrenergic pharmacology and cognition: focus on the prefrontal cortex. Pharmacol Ther. 2007;113:523–536.
14.
MaCLArnstenAFLiBM. Locomotor hyperactivity induced by blockade of prefrontal cortical alpha2-adrenoceptors in monkeys. Biol Psychiatry. 2005;57:192–195.
15.
HuntRDArnstenAFTAsbellMD. An open trial of guanfacine in the treatment of attention-deficit hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 1995;34:50–54.
16.
ScahillLChappellPBKimYS. A placebo-controlled study of guanfacine in the treatment of children with tic disorders and attention deficit hyperactivity disorder. Am J Psychiatry. 2001;158:1067–1074.
17.
ScahillLAmanMGMcDougleCJ. A prospective open trial of guanfacine in children with pervasive developmental disorders. J Child Adolesc Psychopharmacol. 2006;16:589–598.
18.
CarterJCCaponeGTGrayRM. Autistic-spectrum disorders in Down syndrome: further delineation and distinction from other behavioral abnormalities. Am J Med Genet B Neuropsychiatr Genet. 2007;144B:87–94.
19.
EksteinSGlickBWeillM. Down syndrome and attention-deficit/hyperactivity disorder (ADHD). J Child Neurol. 2011; 26:1290–5.
20.
APA. 1994. Diagnostic and Statistical Manual of Mental Disorders IV. 4th ed. Washington, DC: American Psychiatric Association.
AmanMSinghNStewartA. The Aberrant Behavior Checklist: a behavior rating scale for the assessment of treatment effects. Am J Ment Defic. 1985;89:485–491.
23.
AmanMSinghNStewartA. Psychometric characteristics of the Aberrant Behavior Checklist. Am J Ment Defic. 1985;89:492–502.
24.
CaponeGTGradosMAKaufmannWE. Down syndrome and comorbid autism-spectrum disorder: characterization using the aberrant behavior checklist. Am J Med Genet. 2005;134:373–380.
25.
CaponeGGradosMGoyalP. Risperidone use in children with Down syndrome, severe intellectual disability and co-morbid autistic spectrum disorder. J Dev Behav Pediatr. 2008;29:106–116.
26.
YudofskySSilverJJacksonW. The overt aggression scale for the objective rating of verbal and physical aggression. Am J Psychiatry. 1986;143:35–39.
27.
CohenJ. 1988. Statistical Power Analysis for the Behavioral Sciences. Hillsdale, NJ: Lawrence Erlbaum Associates.
28.
CoeDAMatsonJLRussellDW. Behavior problems of children with Down syndrome and life events. J Autism Dev Disord. 1999;29:149–156.
29.
SchnoesCJKuhnBRWorkmanEF. Pediatric prescribing practices for clonidine and other pharmacologic agents for children with sleep disturbance. Clin Pediatr (Phila). 2006;45:229–238.
30.
SpiegelRDeVosJE. Central effects of guanfacine and clonidine during wakefulness and sleep in healthy subjects. Br J Clin Pharmacol. 1980;10(suppl 1):165S–168S.
31.
CrosbieJPerusseDBarrC. Validating psychiatric endophenotypes: inhibitory control and attention deficit hyperactivity disorder. Neurosci Biobehav Rev. 2008;32:40–55.
32.
PoissantHNeaultIDallaireS. Development of self-regulation and inhibition in children exhibiting attention deficit disorder with or without hyperactivity (ADHD). Encephale. 2008;34:161–169.
33.
MatthysWVanderschurenLJSchutterDJ. Impaired neurocognitive functions affect social learning processes in oppositional defiant disorder and conduct disorder: implications for interventions. Clin Child Fam Psychol Rev. 2012;15:234–246.
34.
MatthysWVanderschurenLJSchutterDJ. The neurobiology of oppositional defiant disorder and conduct disorder: altered functioning in three mental domains. Dev Psychopathol. 2013;25:193–207.
35.
BorellaECarrettiBLanfranchiS. Inhibitory mechanisms in Down syndrome: is there a specific or general deficit?Res Dev Disabil. 2013;34:65–71.
36.
DaunhauerLAFidlerDJHahnL. Profiles of everyday executive functioning in young children with Down syndrome. Am J Intellect Dev Disabil. 2014;119:303–318.
